4. Their main game is to sell SPL altogether and again they are delaying launch to keep it clean and maybe give Astra Zeneca or some major Pharma buyer the opportunity to launch it all under their own brand.
I think this ship has sailed - it's a bit late to pull this back when you have contracts signed for three major regions now with two different providers .... not sure that Aspen and Mundipharma would relinquish distribution rights that easily ? Just my opinion
I, like I am sure many on here, can't really offer any other justification for the delay in Fluerstat launch in Australia & New Zealand apart from very poor form / communications of Starpharma Management ... sorry
SPL Price at posting:
$1.23 Sentiment: Hold Disclosure: Held
